Obesity and Alzheimer's: Your Body May Be Setting The Stage For Alzheimer's Without You Knowing It

Obesity may be "feeding" Alzheimer's without you realizing it. Scientists have discovered that a type of body fat can trigger brain inflammation, damage neurons, and accelerate the accumulation of toxic proteins linked to dementia. The discovery could change how we understand Alzheimer's.

For many years, doctors have observed something intriguing: people with obesity in middle age have a higher risk of developing Alzheimer's disease in the future. But until now, scientists still didn't understand exactly how excess body fat could directly affect the brain and accelerate the onset of dementia.

Now, a new study has provided one of the most detailed explanations ever found. Researchers discovered that a specific type of fat present in the body can trigger dangerous changes in the brain, favoring inflammation, the accumulation of toxic proteins, and damage to brain cells linked to memory.

The research focused on a molecule called phosphatidylethanolamine, a type of fat naturally present in cell membranes. Under normal conditions, it is essential for the functioning of the body. The problem begins when its levels become excessively high, something common in people with obesity.

Scientists have realized that this excess fat is not restricted to the body. It also affects the brain. According to the study, the molecule alters the functioning of brain cell membranes and interferes with communication between neurons and cells of the brain's immune system.

To investigate this, researchers used an extremely advanced combination of laboratory techniques. They analyzed human tissues, studied animal models of Alzheimer's and applied different methods of brain imaging, genetics and molecular analysis. The objective was to observe how the brain reacts when there is an excess of this specific fat.

One of the most important parts of the study was the use of analyzes called “multiomics”. In simple terms, this means that scientists studied several layers of the organism at the same time: the types of fat present in the cells, the genes activated, the proteins produced and even the behavior of the brain's immune cells. This allowed us to create a much more complete picture of what was happening inside the brain.

Researchers have also used genetically engineered mouse models to develop Alzheimer's-like symptoms. Some of these animals were fed high-fat diets, simulating human obesity. Afterwards, scientists observed changes in the memory, behavior and brain functioning of these animals.

The results were alarming. The excess of this fat caused an abnormal accumulation of toxic proteins associated with Alzheimer's, especially beta-amyloid, one of the main hallmarks of the disease. Furthermore, the brain began to accumulate small "droplets" of fat inside the brain's immune cells, called microglia.

These cells normally function as a cleaning and defense team for the brain. However, when they become overloaded with fat, they begin to malfunction. Instead of protecting neurons, they enter an inflammatory state and contribute to brain damage.

The study also revealed that other immune system cells, called T cells, began to show signs of exhaustion, as if the brain were trapped in a continuous state of inflammation and wear and tear. This environment further favors brain degeneration.

Another important finding was that these alterations appear to directly affect the structure of nerve cell membranes. This interferes with how important proteins are processed within the brain, further facilitating the production of toxic substances linked to Alzheimer's.

Researchers then tested a possible solution. They used a substance called ebselen, capable of helping restore the balance of these fats in the body. In animal models, the treatment reduced brain inflammation, improved the functioning of immune cells, and led to improved cognitive performance.

Although the results still need to be confirmed in humans, scientists believe this discovery could pave the way for new treatments focused not only on the brain, but also on metabolism and obesity as part of Alzheimer's prevention.

The research reinforces an increasingly strong idea in science: the brain does not function in isolation from the rest of the body. Metabolic problems, chronic inflammation, and obesity can profoundly alter brain function over the years. Moreover, the study suggests that taking care of metabolic health during middle age may be one of the most important ways to protect the brain against dementia in the future.

READ MORE:

Obesity-driven phosphatidylethanolamine dysregulation impairs neuroimmune crosstalk and accelerates Alzheimer’s pathogenesis

Li Yang, Jianting Sheng, Shaohua Qi, Zheng Yin, Michael Chan, Yuliang Cao, Hong Zhao, Zhihao Wan, Bill Chan, Ju Young Ahn, Xiaohui Yu, Matthew Vasquez, Shan Xu, Xianlin Han, Weiming Xia, Willa A. Hsueh and Stephen T. C. Wong

Molecular Neurodegeneration. Volume 21, article number 25 (2026)DOI: 10.1186/s13024-026-00943-3

Abstract: 

Midlife obesity is a major modifiable risk factor for Alzheimer’s disease (AD), yet the lipid-mediated mechanisms linking peripheral metabolic dysfunction to brain pathology remain poorly understood. In particular, how adipose-derived lipid perturbations influence immune and neuronal compartments in the brain has not been fully elucidated. We employed an integrative multi-omics approach combining quantitative lipidomics, single-nucleus RNA sequencing, proteomics, and high-resolution imaging to characterize the metabolic alterations associated with obesity in both peripheral and central tissues. Functional assessments were performed in AD mouse models to evaluate neuroimmune responses and behavioral outcomes. Statistical analyses were performed using appropriate univariate and multivariate methods, with multiple testing correction applied where applicable. We identified elevated phosphatidylethanolamine (PE) abundance as a metabolic hallmark of obesity. Excess PE accumulation led to disrupted lipid homeostasis and ectopic lipid droplet deposition in the brain, resulting in functional exhaustion of T cells, impaired microglial identity and signaling, and enhanced amyloidogenic processing in excitatory neurons. These effects were linked by membrane remodeling as a unifying structural mechanism. Pharmacological targeting of PE homeostasis using the redox-active compound ebselen ameliorated lipid dysregulation, restored neuroimmune function, and improved cognitive performance in AD models. Our study reveals a critical role for PE in coordinating immune-neuronal crosstalk under metabolic stress. These findings suggest that lipid remodeling serves as a structural nexus linking obesity to AD progression, and support the potential of lipid-directed interventions as therapeutic strategies for metabolic-risk-associated neurodegeneration.